Guardant Health (NASDAQ:GH) Given “Buy” Rating at BTIG Research

BTIG Research reiterated their buy rating on shares of Guardant Health (NASDAQ:GH) in a research report report published on Monday,Benzinga reports. BTIG Research currently has a $70.00 price target on the stock.

A number of other brokerages have also recently weighed in on GH. Wells Fargo & Company began coverage on shares of Guardant Health in a research note on Monday. They set an “overweight” rating and a $72.00 price objective on the stock. Raymond James Financial lifted their target price on Guardant Health from $59.00 to $61.00 and gave the stock an “outperform” rating in a report on Thursday, July 31st. Evercore ISI upgraded shares of Guardant Health to a “strong-buy” rating in a research report on Monday, July 14th. Scotiabank raised their price objective on shares of Guardant Health from $57.00 to $60.00 and gave the company a “sector outperform” rating in a research report on Thursday, July 31st. Finally, Mizuho raised their price objective on shares of Guardant Health from $60.00 to $65.00 and gave the company an “outperform” rating in a research report on Friday, June 13th. One analyst has rated the stock with a Strong Buy rating and eighteen have given a Buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $59.00.

Guardant Health Stock Up 1.1%

Shares of NASDAQ GH opened at $59.78 on Monday. Guardant Health has a fifty-two week low of $20.14 and a fifty-two week high of $68.00. The firm’s 50-day simple moving average is $54.65 and its 200 day simple moving average is $48.41. The stock has a market cap of $7.46 billion, a P/E ratio of -17.84 and a beta of 1.45.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Wednesday, July 30th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.08. The company had revenue of $232.09 million for the quarter, compared to the consensus estimate of $211.19 million. During the same quarter in the prior year, the firm earned ($0.84) earnings per share. Guardant Health’s revenue for the quarter was up 31.0% compared to the same quarter last year. Guardant Health has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Guardant Health will post -2.9 earnings per share for the current fiscal year.

Insider Activity at Guardant Health

In related news, Director Medina Manuel Hidalgo sold 2,165 shares of the business’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $54.16, for a total value of $117,256.40. Following the completion of the sale, the director owned 851 shares of the company’s stock, valued at approximately $46,090.16. The trade was a 71.78% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Amirali Talasaz sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $50.88, for a total value of $5,088,000.00. Following the completion of the sale, the chief executive officer directly owned 1,971,830 shares of the company’s stock, valued at approximately $100,326,710.40. The trade was a 4.83% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 402,691 shares of company stock valued at $23,069,965. 6.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Guardant Health

Several large investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new stake in Guardant Health during the fourth quarter worth approximately $79,000. 111 Capital bought a new stake in Guardant Health during the fourth quarter worth approximately $254,000. GAMMA Investing LLC boosted its position in Guardant Health by 11,765.1% during the first quarter. GAMMA Investing LLC now owns 17,679 shares of the company’s stock worth $7,530,000 after purchasing an additional 17,530 shares during the period. Rhumbline Advisers boosted its position in Guardant Health by 4.9% during the first quarter. Rhumbline Advisers now owns 175,432 shares of the company’s stock worth $7,473,000 after purchasing an additional 8,202 shares during the period. Finally, MRA Advisory Group bought a new stake in Guardant Health during the first quarter worth approximately $651,000. Institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.